Preclinical data presented at the Society for Immunotherapy of Cancer Annual Meeting show the potential of cancer-targeted myeloid cells, reprogrammed in the body through the use of chimeric antigen receptor–encoding mRNA encapsulated in lipid nanoparticles, to shrink metastases and suppress tumor growth.

©2023 American Association for Cancer Research
2023
American Association for Cancer Research
You do not currently have access to this content.